Cardiology - Original Articles
Early Access
Optimizing cardiovascular risk control after an acute coronary syndrome: the role of a structured follow-up program
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 5 December 2025
67
Views
64
Downloads
Authors
Effective secondary prevention after an acute coronary syndrome (ACS) remains a challenge, particularly in achieving optimal control of cardiovascular risk factors (CVRF). This study aimed to evaluate the impact of a Structured Coronary-Disease Follow-up Program (SCCC) on the management of key CVRFs 12 months after ACS. A comparative analysis was conducted between patients enrolled in the SCCC and a historical cohort receiving routine care (RCC). Primary outcomes included low-density lipoprotein cholesterol (LDL-C), glycated hemoglobin (HbA1c) in patients with diabetes mellitus, systolic blood pressure (SBP), and smoking cessation at 12 months. Intragroup changes were assessed using paired Wilcoxon tests, while the program’s impact was evaluated through analysis of covariance (ANCOVA) and logistic regression. A total of 521 patients were included (237 SCCC, 284 RCC). In the SCCC group, significant reductions were observed in LDL-C [from 99 (interquartile range, IQR: 74-126) to 52 (IQR: 43-66) mg/dL, p<0.001], HbA1c [from 7.00% (IQR 6.30-7.60) to 6.40% (IQR 6.10-6.85), p<0.001], and SBP [from 134 (IQR 120-145) to 130 (IQR 117-140) mmHg, p<0.001]. ANCOVA confirmed the program’s significant impact on LDL-C (β=-13.0, p<0.001), HbA1c (β=-0.49, p=0.026), and SBP (β=-3.5, p=0.018). No significant difference was observed in smoking cessation (p>0.9). In conclusion, implementation of a structured follow-up program after ACS was associated with improved control of LDL-C, HbA1c, and SBP, supporting the role of coordinated post-ACS care in enhancing CVRF management.
Downloads
Download data is not yet available.
Citations
Eisen A, Giugliano RP, Braunwald E. Updates on acute coronary syndrome: a review. JAMA Cardiol 2016;1:718-30. DOI: https://doi.org/10.1001/jamacardio.2016.2049
Gitt AK, Lautsch D, Ferrières J, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. Atherosclerosis 2017;266:158-66. DOI: https://doi.org/10.1016/j.atherosclerosis.2017.08.013
Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016;4:256. DOI: https://doi.org/10.21037/atm.2016.06.33
Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022;43:716-99. DOI: https://doi.org/10.1093/eurheartj/ehac064
Sabouret P, Lemesle G, Bellemain-Appaix A, et al. Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper. Arch Med Sci 2022;18:839-54. DOI: https://doi.org/10.5114/aoms/150321
Panattoni G, Monzo L, Gugliotta M, et al. Optimal management of patients after acute coronary syndrome. Eur Heart J Suppl 2023;25:C84-9. DOI: https://doi.org/10.1093/eurheartjsupp/suad039
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227-337. DOI: https://doi.org/10.1093/eurheartj/ehab484
Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023;44:4043-140. DOI: https://doi.org/10.1093/eurheartj/ehad192
De Bacquer D, Astin F, Kotseva K, et al. Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. Eur J Prev Cardiol 2022;29:383-95. DOI: https://doi.org/10.1093/eurjpc/zwab115
Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high, middle-, and low-income countries. JAMA 2013;310:959-68. DOI: https://doi.org/10.1001/jama.2013.184182
Reiner Ž, De Backer G, Fras Z, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries—findings from the EUROASPIRE IV survey. Atherosclerosis 2016;246:243-50. DOI: https://doi.org/10.1016/j.atherosclerosis.2016.01.018
Khan Z, Gul A, Yousif Y, Gupta A. A systematic review of lipid management in secondary prevention and comparison of international lipid management pathways. Cureus 2023;15:e35463. DOI: https://doi.org/10.7759/cureus.35463
Taylor RS, Fredericks S, Jones I, et al. Global perspectives on heart disease rehabilitation and secondary prevention. Eur Heart J 2023;44:2515-25. DOI: https://doi.org/10.1093/eurheartj/ehad225
Silva V, Matos Vilela E, Campos L, et al. Suboptimal control of cardiovascular risk factors in myocardial infarction survivors in a cardiac rehabilitation program. Rev Port Cardiol 2021;40:911-20. DOI: https://doi.org/10.1016/j.repc.2021.01.015
Peters AE, Keeley EC. Trends and predictors of participation in cardiac rehabilitation following acute myocardial infarction. J Am Heart Assoc 2018;7:e007663. DOI: https://doi.org/10.1161/JAHA.117.007664
Tilgner N, Nehls D, Lichtmess C, et al. Adherence to exercise and fitness following exercise-based outpatient cardiac rehabilitation: a cross-sectional survey for Germany. BMC Sports Sci Med Rehabil 2022;14:191. DOI: https://doi.org/10.1186/s13102-022-00585-0
Wittlinger T, Schwaab B, Völler H, et al. Efficacy of lipid-lowering therapy during cardiac rehabilitation in patients with diabetes mellitus and coronary heart disease. J Cardiovasc Dev Dis 2021; 8:105. DOI: https://doi.org/10.3390/jcdd8090105
Taylor RS, Dalal HM, McDonagh STJ. The role of cardiac rehabilitation in improving cardiovascular outcomes. Nat Rev Cardiol 2022;19:180-94. DOI: https://doi.org/10.1038/s41569-021-00611-7
Jackson C, Shahsahebi M, Wedlake T, DuBard CA. Timeliness of outpatient follow-up: an evidence-based approach for planning after hospital discharge. Ann Fam Med 2015;13:115-22. DOI: https://doi.org/10.1370/afm.1753
Fontes JP, Vilela EM, Durazzo A, Teixeira M. Current state of cardiac rehabilitation in Portugal: results of the 2019 national survey. Rev Port Cardiol 2021;40:877-87. DOI: https://doi.org/10.1016/j.repc.2021.01.013
Haute Autorité de Santé. Guide parcours de soins: Maladie coronarienne stable [Internet]. Saint-Denis La Plaine: HAS; 2016 [cited 2025 Mar 1]. Available from: https://www.has-sante.fr/jcms/c_1761791/fr/guide-parcours-de-soins-maladie-coronarienne-stable
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-77. DOI: https://doi.org/10.1093/eurheartj/ehz425
WHO. ICD-10: international statistical classification of diseases and related health problems. 10th rev, 2nd ed. 2004. Available from: https://icd.who.int/browse10/2019/en.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2018;40:237-69. DOI: https://doi.org/10.1093/eurheartj/ehy856
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021.
British Heart Foundation. The national audit of cardiac rehabilitation. Available from: https://www.bhf.org.uk/-/media/files/information-and-support/publications/hcps/nacr-quality-and-outcomes-report2019.pdf.
Denegri A, Rossi VA, Vaghi F, et al. A patient-centered multidisciplinary cardiac rehabilitation program improves glycemic control and functional outcome in coronary artery disease. Cardiol J 2022;29:72-9. DOI: https://doi.org/10.5603/CJ.a2020.0006
Canoy D, Nazarzadeh M, Copland E, et al. How much lowering of blood pressure is required to prevent cardiovascular disease? Curr Cardiol Rep 2022;24:851-60. DOI: https://doi.org/10.1007/s11886-022-01706-4
Lovatt S, Wong CW, Holroyd E, et al. Smoking cessation after acute coronary syndrome: a systematic review and meta-analysis. Int J Clin Pract 2021;75:e14894. DOI: https://doi.org/10.1111/ijcp.14894
Kite TA, Pallikadavath S, Gale CP, et al. The direct and indirect effects of COVID-19 on acute coronary syndromes. Heart Fail Clin 2023;19:185-96. DOI: https://doi.org/10.1016/j.hfc.2022.08.002
Ethics Approval
This study was approved by the Ethics Committee of Hospital Vila Nova de Gaia/Espinho under approval number 138/2022.How to Cite
“Optimizing Cardiovascular Risk Control After an Acute Coronary Syndrome: The Role of a Structured Follow-up Program”. 2025. Monaldi Archives for Chest Disease, December. https://doi.org/10.4081/monaldi.2025.3621.
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.